Company news
Median Technologies news in 2025
Median Technologies's news releases, calls and decks from 2025, newest first.
Median Technologies Partners With Leading U.S. Healthcare Company to Bring eyonis® LCS to Patients Across the U.S. and Europe
December 8, 2025
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of November 30, 2025
December 3, 2025
Median Technologies to Showcase AI-Powered Software as a Medical Device eyonis® LCS for Lung Cancer Screening at the RSNA 2025 Annual Meeting
November 25, 2025
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of October 31, 2025
November 13, 2025
Median Technologies Appoints Didric Cederholm to Its Board of Directors
November 3, 2025
Median Technologies Reports First-Half 2025 Financial Results and Provides Key Q3 2025 Business Results
October 23, 2025
Median Technologies Receives €19 Million From the European Investment Bank, Corresponding to the First Tranche Under the 2025 Loan Facility
October 21, 2025
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on October 31, 2025
October 13, 2025
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of September 30, 2025
October 6, 2025
Median Technologies Business Update Following Successful Financing
September 22, 2025
Median Technologies: H2 2025 Financial Communication Calendar
September 8, 2025
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of August 31, 2025
September 4, 2025
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31, 2025
August 7, 2025
Median Technologies Has Completed a Capital Increase of € 23.9 Million
August 1, 2025
CORRECTING and REPLACING: Following the signature of a financial agreement for up to €37.5 million with the EIB, Median Technologies launches an approximately €22 million capital increase to support commercialization of eyonis® LCS in the U.S....
July 23, 2025
Following the Signature of a Financial Agreement for up to €37.5 Million With the EIB, Median Technologies Launches an Approximately €22.0 Million Capital Increase to Support Commercialization of eyonis® LCS in the U.S. and to Finance Expansion...
July 21, 2025
Median Technologies Signs Financial Agreement for up to €37.5 Million New Financing Facility With the European Investment Bank (EIB)
July 11, 2025
Median Technologies: Half Year Liquidity Contract Statement
July 9, 2025
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2025
July 7, 2025
Median Technologies Files European Application for Class IIb CE Marking of Its AI-Based Software as a Medical Device for Lung Cancer Screening, eyonis® LCS
July 1, 2025
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025
June 10, 2025
Median Technologies announces the availability of the preparatory documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 17, 2025
May 28, 2025
Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ASCO 2025
May 27, 2025
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2025
May 16, 2025
Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS
May 14, 2025
Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025
May 12, 2025
Median Technologies to Participate in Several Investor Conferences in May and June 2025
May 6, 2025
Median Technologies Reports Full-year 2024 Financial Results
April 29, 2025
Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements
April 24, 2025